CAD occurs when one or more of the coronary arteries are narrowed or occluded, resulting in the decrease of blood supply to the heart muscle. It is regarded as the third leading cause of death worldwide.​

The disease recurs in 30% of the patients who have received surgical procedures and medication, which are the most common treatments. Furthermore, about 10% of the patient population does not respond to medication and cannot undergo surgery.​

Engensis (VM202) has the potential to promote blood vessel formation in the ischemic area by HGF-based angiogenesis. In addition, the HGF-based angiogenesis may also contribute to cardiac muscle function improvement through the suppression of apoptosis and cardiac fibrosis​